Novartis AG is set to overhaul its eye care business Alcon after a lackluster 2015, focusing on its core Surgical and Vision Care business by cleaving its ophthalmic pharmaceuticals business and repositioning it into the Pharmaceuticals division.
Novartis CEO Joe Jimenez said during the company's annual results presentation that after "expansive analysis" of the Alcon business over...




